Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Staining instrument family

New pathology lab solutions debut at ECP 2025

Agilent Technologies Inc. announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of…

News • Patient involvement enables research

Tumor vesicles as a promising biomarker for early cancer detection

Tumor vesicles may serve as early indicators of cancer and help monitor the effectiveness of treatments. Now, researchers discovered a new way to detect these vesicles.

Article • Sustainable workflows

Designing the laboratory of the future

Laboratories across Europe are embracing sustainability through paperless workflows and automation. In this guest article, Gavin Hirst, Clinical Flow Cytometry Account Manager at Beckman Coulter Life…